Hyderabad, Dec 24, 2014
Dr. Reddy’s Laboratories on Tuesday said it had launched Valganciclovir tablets, an anti-viral drug in the U.S. market after receiving U.S. Food and Drug Administration (US FDA) approval.
The product is a therapeutic equivalent generic version of Valcyte made by Roche. A statement from the company said the Valcyte tablets brand has U.S. sales of around $440 million for the 12 month ending October, 2014, according to IMS data. Dr. Reddy’s Valganciclovir tablets in 450 mg strength is available in bottle counts of 60, the statement said. Earlier, the U.S. FDA had granted final approval to Dr. Reddy’s and U.S.-based Endo International to make cheaper copies of Valcyte. But the US FDA had stripped the company of its tentative approval to launch the copy of the drug. Business Line
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…